比利时婴儿在肺炎球菌结合疫苗规划实施9年后的鼻咽部肺炎链球菌携带率与密度
比利时在肺炎球菌结合疫苗(PCV)规划由PCV7转为PCV13再转为PCV10的背景下,于2016年启动为期3年的鼻咽部携带研究。第一年基线评估显示,日托中心婴儿培养法携带率为60.8%(462/760),LytA法为80.1%(603/753);急性中耳炎(AOM)婴儿分别为69.2%(27/39)和82.1%(32/39)。PCV13血清型携带率低,青霉素耐药罕见。
要点
- 日托中心婴儿培养法肺炎链球菌携带率为60.8%(462/760),LytA法为80.1%(603/753)。
- AOM婴儿培养法携带率为69.2%(27/39),LytA法为82.1%(32/39)。
- 日托中心PCV13血清型频率为5.4%,AOM为7.7%,青霉素耐药罕见(<0.5%)。
核心结论
- PCV13引入规划四年后,比利时婴儿中PCV13血清型携带罕见,青霉素耐药罕见。
- 在PCV规划转换背景下,持续监测是必要的。
研究设计与样本
- 研究为为期3年的鼻咽部携带研究,2016年规划转换期间启动,第一年评估为基线测量。
- 纳入6-30月龄、采样前7天内未使用抗生素的婴儿:来自85个随机选择的日托中心(DCC)之一,或因AOM就诊于研究培训的全科医生和儿科医生。
- 记录人口学和临床特征,采集单次鼻咽拭子,进行肺炎链球菌培养、抗生素耐药筛查和血清分型,以及靶向LytA的定量Taqman实时PCR(qRT-PCR)。
主要发现
- 培养法携带率:DCC为60.8%(462/760),AOM为69.2%(27/39);LytA法携带率:DCC为80.1%(603/753),AOM为82.1%(32/39)。
- LytA阳性日托样本平均肺炎球菌DNA载量为6.5×10^6 copies/µl(95%CI=3.9-9.2×10^6,中位数=3.5×10^5);DNA载量与普通感冒体征正相关,与既往抗生素使用负相关。
- 培养法13种PCV血清型频率:DCC为5.4%,AOM为7.7%;最常见为19F和14;两个人群中血清型3、6A、19A频率均低于0.5%。
- 日托中心主要非PCV血清型为23B和23A,AOM婴儿为11A。
- 日托中心对青霉素耐药罕见(<0.5%),对左氧氟沙星无耐药;32.7%和16.9%分离株分别对复方磺胺甲噁唑和红霉素耐药。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In Belgium, the infant pneumococcal conjugate vaccine (PCV) programme changed from PCV7 (2007-2011) to PCV13 (2011-2015) and to PCV10 (2015-2016). A 3-year nasopharyngeal carriage study was initiated during the programme switch in 2016. Main objective of the year 1 assessment was to obtain a baseline measurement of pneumococcal carriage prevalence, carriage density, serotype distribution and antibiotic resistance. MATERIALS/METHODS: Two infant populations aged 6-30 months and without use of antibiotics in the seven days prior to sampling were approached: (1) attending one of 85 randomly selected day-care centres (DCC); (2) presenting with AOM at study-trained general practitioners and paediatricians. Demographic and clinical characteristics were documented and a single nasopharyngeal swab was taken. S. pneumoniae were cultured, screened for antibiotic resistance and serotyped, and quantitative Taqman real-time PCR (qRT-PCR) targeting LytA was performed. RESULTS: Culture-based (DCC: 462/760; 60.8% - AOM: 27/39; 69.2%) and LytA-based (DCC: 603/753; 80.1% - AOM: 32/39; 82.1%) carriage prevalence was high. Average pneumococcal DNA load in LytA-positive day-care samples was 6.5 × 106 copies/µl (95%CI = 3.9-9.2 × 106, median = 3.5 × 105); DNA load was positively associated with signs of common cold and negatively with previous antibiotic use. Culture-based frequency of 13 pneumococcal vaccine (PCV) serotypes was 5.4% in DCC and 7.7% in AOM, with 19F and 14 being most frequent, and frequencies below 0.5% for serotypes 3, 6A, 19A in both populations. Predominant non-PCV serotypes were 23B and 23A in day-care and 11A in infants with AOM. In day-care, resistance to penicillin was rare (<0.5%) and absent against levofloxacin; 32.7% and 16.9% isolates were cotrimoxazole- and erythromycin-resistant respectively. CONCLUSION: Four years after PCV13 introduction in the vaccination programme, PCV13 serotype carriage was rare in infants throughout Belgium and penicillin resistance was rare. Continued surveillance in the context of a PCV programme switch is necessary.
引用
- Wouters I, Van Heirstraeten L, Desmet S, et al. Nasopharyngeal s. pneumoniae carriage and density in Belgian infants after 9 years of pneumococcal conjugate vaccine programme. Vaccine. 2017. PMID: 29180027. doi:10.1016/j.vaccine.2017.11.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。